ClinicalTrials.gg
Status unknownNCT03425214NC-TCSP-IRMfUpdated Feb 9, 2018

Exploration of the Reward System by Functional MRI in Narco-cataplexy Patients With and Without REM Sleep Behavior Disorder

An interventional study of fMRI and Videopolysomnography in Narcolepsy and Cataplexy, sponsored by University Hospital, Clermont-Ferrand. Status unknown at 1 site in France. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-02-09.

Primary conditionCataplexyRegistry: NarcolepsyReclassifiedWhy we changed it
Registry
Narcolepsy — the first condition term the registry derived for this study.
ClinicalTrials.gg
Cataplexy
Why
  1. The study's listed conditions name Cataplexy, a narrower term within Narcolepsy.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University Hospital, Clermont-Ferrand · Not applicable, Interventional, and Diagnostic

The sponsor has not verified this record recently (last verified Feb 2018), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Up to 50% of Narcolepsy-cataplexy (NC) patients suffer from REM sleep behavior disorder (RBD), a parasomnia.

A strong link was found between RBD and impulse control disorders (ICD) in Parkinson disease (PD) patients. ICD are thought to be related to a dysfunction of meso-cortico-limbic pathways which belong to the so called ''reward system''.

A recent study in IRMf shows that RBD is associated with impaired reward system.

A strong link was found between these two disorders and therefore we believe that RBD is associated with impaired reward system in NC

The main objective of this study is to evaluate differences in brain activation between NC patients with and without RBD.

The investigators hypothesize that NC patients with RBD have a more severe dysfunction of the reward system (hypoactivation of the meso-cortico-limbic pathway) than patients without RBD.

Read the detailed description

Type of study: Prospective, case control study.

Number of centers: 3 (Clermont-Ferrand, Vichy and Montlucon)

Patients :

The study will be performed in 66 subjects (22 PD patients with RBD, 22 PD patients without RBD and 22 healthy volunteers, age-and sex-matched without any contraindications to perform an MRI)

Study Performance :

During the first visit (Baseline, inclusion visit, 2 hours), each subject will perform a clinical and neurological examination and neuropsychological assessment (depression by the Beck Depression Inventory (BDI); apathy by the Lille Apathy Rating Scale (LARS), impulsivity by the Urgency, lack of Premeditation, lack of Perseverance, Sensation Seeking scale (UPPS)) Eligible patients will be welcomed for a video Polysomnography in the sleep center, for one night (Month 1, 1 night) and in a subsequent visit at the MRI department for the functional MRI (Month 1, 1 hour). This session will be of about 45 minutes. The reward system will be explore using an experimental task during functional Magnetic Resonance Imaging (fMRI). The name of this task is the"monetary incentive delay task".

02

Conditions studied

  • Narcolepsy
  • Cataplexy

Browse trials for

Keywords

  • functional MRI
  • Reward system
  • REM sleep behaviour disorder
  • Narco-cataplexy
03

In context

Cataplexy Reclassified

31 studies on the registry are indexed under Cataplexy; 5 are open to participants now.

This study's planned enrollment of 66 is below the median of 117 across 27 interventional studies indexed under Cataplexy.

Browse Cataplexy studies →

Lead sponsor

University Hospital, Clermont-Ferrand is the lead sponsor of 859 studies on the registry; 179 are open to participants now.

Compared within Cataplexy, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Narcolepsy. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Men or women, right handed, 18 to 80 years
  • Patients with type 1 Narcolepsy according to the criteria of the International Classification of Sleep, 3rd version, 2014
  • Acceptance of the protocol and signature of a written consent
  • Social security affiliation

Exclusion criteria

Exclusion Criteria:

  • Previous history of psychosis or psychiatric disease
  • History of stroke or vascular lesion on MRI.
  • Perceptual disorder (vision, hearing) may hinder the realization of the protocols,
  • Dementia defined by a score across (MoCA) \<26/30.
  • Major depressive state defined by a score scale Beck Depression Inventory (BDI)> 14
  • Apathy defined by a score ≥ 14 on the Apathy Scale of Starkstein. Patients with a score ≥ this one will be excluded.
  • Usual to MRI, knowing that no contrast agent injection is performed.
  • Pregnant woman.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    NC with RBD

    fMRI and video polysmnography

    Other: fMRI · Other: Videopolysomnography

  • Experimental
    NC without RBD

    fMRI and video polysomnography

    Other: NC (narcolepsy-cataplexy)

  • Experimental
    control group (healthy subjects)

    fMRI

    Other: fMRI

Interventions

  • OtherfMRI

    Session will be of about 45 minutes. The reward system will be explore using an experimental task during functional Magnetic Resonance Imaging (fMRI). The name of this task is the"monetary incentive delay task".

  • OtherVideopolysomnography

    Video polysomnography will be perform in the sleep center during one night if patient did not have vPSG for 1 year.

  • OtherNC (narcolepsy-cataplexy)

    The investigators hypothesize that NC patients with RBD have a more severe dysfunction of the reward system (hypoactivation of the meso-cortico-limbic pathway) than patients without RBD.

06

What researchers measure

Primary outcomes

  1. Measure of BOLD signal variation in each region of interest

    BOLD signal variation in each region of interest (ventral tegmental area, accumbens nucleus, limbic cortex, prefrontal cortex) measured during fMRI

    Time frame: at Month 1

Secondary outcomes

  1. reaction time to the task

    Time frame: at Month 1

  2. performance score to the task

    Time frame: at Month 1

  3. Beck Depression Inventory score measured during fMRI

    Time frame: at baseline

  4. Lille Apathy Rating Scale score measured during fMRI

    Time frame: at baseline

  5. impulsivity score by the Urgency measured during fMRI

    Time frame: at baseline

07

Study locations

1 of 1 sites recruiting
  • CHU Clermont-Ferrand
    Clermont-Ferrand, 63003, France
    Recruiting
    • Patrick LACARIN · Contactplacarin@chu-clermontferrand.fr · 04 73 75 11 95
    • Maria-Livia FANTINI · Principal investigator
    • Nicolas VITELLO · Sub investigator
    • Marcel MAILLET-VIOUF · Sub investigator
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 9, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03425214
Collaborators
CH MONTLUCON, Jacques Lacarin Hospital Center
Responsible party
Sponsor
First posted
Feb 7, 2018
Start date
Jan 19, 2018
Primary completion
Jun 30, 2019 (estimated)
Completion
Jun 30, 2019 (estimated)
Last update
Feb 9, 2018

Study contacts

Patrick LACARIN
Contact
placarin@chu-clermontferrand.fr
04 73 75 11 95
Maria-Livia FANTINI
principal investigator · University Hospital, Clermont-Ferrand

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion